Your browser doesn't support javascript.
loading
Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).
Chalmers, J R; Thomas, K S; Apfelbacher, C; Williams, H C; Prinsen, C A; Spuls, P I; Simpson, E; Gerbens, L A A; Boers, M; Barbarot, S; Stalder, J F; Abuabara, K; Aoki, V; Ardeleanu, M; Armstrong, J; Bang, B; Berents, T L; Burton, T; Butler, L; Chubachi, T; Cresswell-Melville, A; DeLozier, A; Eckert, L; Eichenfield, L; Flohr, C; Futamura, M; Gadkari, A; Gjerde, E S; van Halewijn, K F; Hawkes, C; Howells, L; Howie, L; Humphreys, R; Ishii, H A; Kataoka, Y; Katayama, I; Kouwenhoven, W; Langan, S M; Leshem, Y A; Merhand, S; Mina-Osorio, P; Murota, H; Nakahara, T; Nunes, F P; Nygaard, U; Nygårdas, M; Ohya, Y; Ono, E; Rehbinder, E; Rogers, N K.
Afiliação
  • Chalmers JR; Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, U.K.
  • Thomas KS; Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, U.K.
  • Apfelbacher C; Medical Sociology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany.
  • Williams HC; Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, U.K.
  • Prinsen CA; Department of Epidemiology and Biostatistics, EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands.
  • Spuls PI; Department of Dermatology, Academic Medical Center, Amsterdam, the Netherlands.
  • Simpson E; Department of Dermatology, Oregon Health and Science University, Portland, OR, U.S.A.
  • Gerbens LAA; Department of Dermatology, Academic Medical Center, Amsterdam, the Netherlands.
  • Boers M; VU University Medical Center, Amsterdam, the Netherlands.
  • Barbarot S; Department of Dermatology, Nantes University Hospital (CHU de Nantes), France.
  • Stalder JF; Department of Dermatology, Nantes University Hospital (CHU de Nantes), France.
  • Abuabara K; Department of Dermatology, University of California San Francisco, San Francisco, CA, U.S.A.
  • Aoki V; University of São Paulo Medical School, São Paulo, Brazil.
  • Ardeleanu M; Regeneron Pharmaceuticals, Tarrytown, NY, U.S.A.
  • Armstrong J; Galderma, Paris, France.
  • Bang B; LEO Pharma, Ballerup, Denmark.
  • Berents TL; Oslo University Hospital, Oslo, Norway.
  • Burton T; Patient, Nottingham, U.K.
  • Butler L; National Eczema Association, San Rafael, CA, U.S.A.
  • Chubachi T; GlaxoSmithKline, Research Triangle Park, NC, U.S.A.
  • Cresswell-Melville A; Eczema Society of Canada, Keswick, ON, Canada.
  • DeLozier A; Eli Lilly and Company, Indianapolis, IN, U.S.A.
  • Eckert L; Sanofi, Chilly-Mazarin, France.
  • Eichenfield L; Rady Children's Hospital, University of California San Francisco, San Diego, CA, U.S.A.
  • Flohr C; St John's Institute of Dermatology, St Thomas' Hospital, London, U.K.
  • Futamura M; Nagoya Medical Center, Nagoya, Japan.
  • Gadkari A; Regeneron Pharmaceuticals, Tarrytown, NY, U.S.A.
  • Gjerde ES; The Psoriasis and Eczema Association of Norway, Oslo, Norway.
  • van Halewijn KF; Erasmus MC, University Medical Centre, Rotterdam, the Netherlands.
  • Hawkes C; GlaxoSmithKline, Uxbridge, U.K.
  • Howells L; Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, U.K.
  • Howie L; Global Parents for Eczema Research, Brisbane, Australia.
  • Humphreys R; National Eczema Society, London, U.K.
  • Ishii HA; Brazilian Atopic Dermatitis Association (AADA), São Paulo, Brazil.
  • Kataoka Y; Osaka Prefectural Medical Center for Respiratory and Allergic Disease, Osaka, Japan.
  • Katayama I; Osaka University, Osaka, Japan.
  • Kouwenhoven W; Dutch Association for People with Atopic Dermatitis, Nijkerk, the Netherlands.
  • Langan SM; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, U.K.
  • Leshem YA; Beilinson Hospital and Tel Aviv University, Petah Tikva and Tel Aviv, Israel.
  • Merhand S; Association Française de l'Eczéma, Redon, France.
  • Mina-Osorio P; Regeneron Pharmaceuticals, Tarrytown, NY, U.S.A.
  • Murota H; Department of Dermatology, Osaka University, Suita, Japan.
  • Nakahara T; Department of Dermatology, Kyushu University, Fukuoka, Japan.
  • Nunes FP; Eli Lilly and Company, Indianapolis, IN, U.S.A.
  • Nygaard U; Eli Lilly and Company, Indianapolis, IN, U.S.A.
  • Nygårdas M; Sanofi Genzyme, Stockholm, Sweden.
  • Ohya Y; National Centre for Child Health and Development, Tokyo, Japan.
  • Ono E; Osaka University, Osaka, Japan.
  • Rehbinder E; Department of Dermatology, Oslo University Hospital, Oslo, Norway.
  • Rogers NK; Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, U.K.
Br J Dermatol ; 178(5): e332-e341, 2018 05.
Article em En | MEDLINE | ID: mdl-29672835
ABSTRACT
This is the report from the fifth meeting of the Harmonising Outcome Measures for Eczema initiative (HOME V). The meeting was held on 12-14 June 2017 in Nantes, France, with 81 participants. The main aims of the meeting were (i) to achieve consensus over the definition of the core domain of long-term control and how to measure it and (ii) to prioritize future areas of research for the measurement of the core domain of quality of life (QoL) in children. Moderated whole-group and small-group consensus discussions were informed by presentations of qualitative studies, systematic reviews and validation studies. Small-group allocations were performed a priori to ensure that each group included different stakeholders from a variety of geographical regions. Anonymous whole-group voting was carried out using handheld electronic voting pads according to predefined consensus rules. It was agreed by consensus that the long-term control domain should include signs, symptoms, quality of life and a patient global instrument. The group agreed that itch intensity should be measured when assessing long-term control of eczema in addition to the frequency of itch captured by the symptoms domain. There was no recommendation of an instrument for the core outcome domain of quality of life in children, but existing instruments were assessed for face validity and feasibility, and future work that will facilitate the recommendation of an instrument was agreed upon.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Dermatite Atópica Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Dermatite Atópica Idioma: En Ano de publicação: 2018 Tipo de documento: Article